United Capital Financial Advisors LLC Lowers Stake in Pfizer Inc. (NYSE:PFE)

United Capital Financial Advisors LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 29.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 187,057 shares of the biopharmaceutical company's stock after selling 77,726 shares during the quarter. United Capital Financial Advisors LLC's holdings in Pfizer were worth $4,963,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently modified their holdings of PFE. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Pfizer during the fourth quarter valued at approximately $883,000. Gamco Investors INC. ET AL grew its position in Pfizer by 12.9% in the fourth quarter. Gamco Investors INC. ET AL now owns 765,364 shares of the biopharmaceutical company's stock worth $20,305,000 after acquiring an additional 87,621 shares in the last quarter. Gabelli Funds LLC raised its position in Pfizer by 2.3% during the fourth quarter. Gabelli Funds LLC now owns 1,029,725 shares of the biopharmaceutical company's stock valued at $27,319,000 after purchasing an additional 23,375 shares in the last quarter. CacheTech Inc. boosted its holdings in shares of Pfizer by 22.3% in the 4th quarter. CacheTech Inc. now owns 22,976 shares of the biopharmaceutical company's stock worth $610,000 after purchasing an additional 4,191 shares in the last quarter. Finally, Bridgewater Associates LP raised its holdings in shares of Pfizer by 2,211.5% during the 4th quarter. Bridgewater Associates LP now owns 273,839 shares of the biopharmaceutical company's stock valued at $7,265,000 after buying an additional 261,992 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Down 0.5 %

Shares of NYSE PFE traded down $0.12 during trading hours on Monday, hitting $22.03. 9,095,402 shares of the stock were exchanged, compared to its average volume of 40,365,305. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a fifty day moving average price of $24.88 and a 200-day moving average price of $26.15. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $124.91 billion, a PE ratio of 15.62, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 EPS. The company's revenue for the quarter was up 24.7% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on PFE shares. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, UBS Group dropped their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.